Early preclinical researches suggest that NFE2L2 signaling is a significant defense pathway to ferroptosis and contributes to the development of resistance to sorafenib treatment on HCC cells (Sun et al., 2016a). Here, NFE2L2 is linked to hepatocellular carcinoma.